Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BENZONATATE vs DEXTROMETHORPHAN POLISTIREX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.
Dextromethorphan polistirex is an NMDA receptor antagonist and sigma-1 receptor agonist. It inhibits serotonin reuptake and acts on the brain stem cough center to elevate the threshold for coughing.
Symptomatic relief of cough
Symptomatic relief of nonproductive cough associated with upper respiratory tract infections,Off-label: Management of pseudobulbar affect (with quinidine),Off-label: Treatment of neuropathic pain
100 mg to 200 mg orally three times daily as needed for cough.
30-60 mg orally every 12 hours; not to exceed 120 mg in 24 hours.
Terminal elimination half-life is approximately 3–8 hours in adults; prolonged in hepatic impairment.
Terminal half-life: 13–19 hours; clinical context: extended-release formulation due to polistirex complex; time to steady-state: ~3 days
Metabolized by plasma esterases (including pseudocholinesterase) to tetracaine and other metabolites.
Hepatic via CYP2D6 (O-demethylation to dextrorphan, active metabolite). Also undergoes N-demethylation via CYP3A4. Polymorphic metabolism (poor metabolizers at risk of toxicity).
Primarily renal excretion of metabolites; unchanged benzonatate is negligible. Fecal elimination accounts for <5%. Biliary excretion is minimal.
Renal: ~45% as unchanged drug and metabolites (dextrorphan conjugates); fecal: <2%; biliary: minimal
Approximately 75–85% bound primarily to albumin.
~50% bound; primarily to albumin
Approximately 3.5 L/kg, indicating extensive tissue distribution.
Vd: ~5–6 L/kg; clinical meaning: extensive tissue distribution, including CNS
Oral: Estimated 20–30% due to extensive first-pass metabolism.
Oral (polistirex): approximately 50–60% (first-pass metabolism reduces systemic availability)
No specific dosage adjustment is recommended for renal impairment per manufacturer; however, caution and monitoring are advised.
No specific dosing adjustment provided for dextromethorphan polistirex; use with caution in severe renal impairment (Cr Cl < 30 m L/min) due to potential accumulation of metabolites.
No specific dosage adjustment is recommended for hepatic impairment per manufacturer; however, caution is advised.
No specific dosing adjustment provided; use with caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance.
Safety and efficacy have not been established in children under 10 years of age. For children ≥10 years, adult dosing can be considered.
Children 6-12 years: 15-30 mg orally every 12 hours; not to exceed 60 mg in 24 hours. Children 2-5 years: 7.5-15 mg orally every 12 hours; not to exceed 30 mg in 24 hours. Not recommended under 2 years.
Elderly patients may be more sensitive to CNS effects; start at lower end of dosing range (100 mg three times daily) and monitor carefully.
Elderly patients may be more sensitive to anticholinergic effects; use the lowest effective dose and monitor for adverse effects such as sedation and dizziness.
None
No FDA black box warning.
Severe allergic reactions (e.g., bronchospasm, laryngospasm, cardiovascular collapse) have been reported, especially with chewing or sucking capsules.,Capsules must be swallowed whole to avoid oral mucosal anesthesia and choking hazard.,Use with caution in patients with hypersensitivity to ester-type local anesthetics.,Safety and efficacy in children <10 years not established.
Do not use with MAOIs or within 14 days of stopping MAOIs,Risk of serotonin syndrome when used with serotonergic drugs,Caution in patients with G6PD deficiency, hepatic impairment, or chronic cough associated with smoking, asthma, or emphysema,QT prolongation risk at supratherapeutic doses,Misuse potential with high doses causing dissociative effects
Hypersensitivity to benzonatate or related compounds (e.g., tetracaine, procaine)
Concurrent use or within 14 days of MAOIs,Hypersensitivity to dextromethorphan or any component,Use in children under 2 years of age (OTC products)
No significant food interactions. The manufacturer does not list any specific dietary restrictions, but alcohol may enhance central nervous system side effects such as drowsiness.
Avoid grapefruit and grapefruit juice as they may alter metabolism. Take with or without food; food does not significantly affect absorption.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies not available. Theoretical risk of fetal bradycardia and respiratory depression if used near term. Second and third trimesters: Avoid use due to potential for neonatal apnea and withdrawal; benzonatate is a local anesthetic with CNS depressant effects.
No well-controlled studies in pregnant women. Animal studies have not shown evidence of fetal harm. Based on limited human data, risk of major congenital malformations is low. Avoid use in first trimester due to theoretical risk based on weak NMDA antagonism.
No data on excretion in human milk; M/P ratio unknown. Benzonatate and its metabolites may be present in breast milk. Caution advised due to potential for infant CNS depression and apnea. Consider benefit of breastfeeding vs risk of drug exposure.
Limited data; excreted in human breast milk in low amounts (M/P ratio not established). Theoretical risk of CNS depression in infant. Use with caution, especially in neonates or preterm infants. Consider immediate-release formulations if necessary.
No pharmacokinetic studies in pregnancy. Dose adjustments not established. Use lowest effective dose if necessary. Avoid in third trimester due to neonatal risk. Increased plasma volume may reduce drug levels, but lack of data prevents formal dose adjustment recommendations.
No specific dose adjustments recommended for pregnancy; however, use lowest effective dose due to altered pharmacokinetics (increased volume of distribution, decreased plasma protein binding) potentially leading to reduced peak concentrations but unchanged half-life.
Benzonatate is a peripherally acting antitussive that anesthetizes stretch receptors in the respiratory tract. Onset of action is within 15-20 minutes and lasts 3-8 hours. Capsules must be swallowed whole; chewing or sucking can cause oropharyngeal anesthesia and choking hazard. Use with caution in patients with a history of drug allergy to tetracaine or other ester-type anesthetics. It is contraindicated in children under 10 years due to increased risk of adverse effects. Overdose can cause seizures, cardiac arrest, and death; treatment is supportive with no specific antidote.
Dextromethorphan polistirex is an extended-release formulation allowing twice-daily dosing. Its antitussive effect lasts up to 12 hours. Caution in patients with asthma or COPD as it may reduce mucociliary clearance. Avoid concurrent use with MAOIs due to risk of serotonin syndrome. Not effective for chronic cough and should not be used for more than 7 days.
Swallow the capsule whole; do not chew, suck, or crush it, as this can cause numbness in your mouth or throat and increase risk of choking.,Take the medication exactly as prescribed; do not take more than directed.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Contact your doctor if your cough persists for more than 5 days, or if it is accompanied by fever, rash, or persistent headache.,Keep out of reach of children; accidental ingestion can be fatal in children under 10.,Store at room temperature away from moisture and heat.
Do not crush or chew the extended-release capsules or suspension; swallow whole or shake suspension well before use.,Do not exceed recommended doses; may cause drowsiness, avoid driving or operating machinery.,Discontinue use and consult healthcare provider if cough persists more than 7 days or is accompanied by fever, rash, or headache.,Avoid alcohol and other CNS depressants as they may increase sedation.,Inform healthcare provider if you are taking MAOIs (e.g., for depression, Parkinson's) or SSRIs to avoid serotonin syndrome.,Keep out of reach of children; overdose can be fatal.
No interactions on record
"The combination of dextromethorphan, a centrally acting antitussive with NMDA receptor antagonist and sigma-1 receptor agonist properties, and aceprometazine, a phenothiazine neuroleptic with strong antihistaminergic and moderate anticholinergic and antidopaminergic effects, can result in additive central nervous system depression. This interaction may lead to excessive sedation, respiratory depression, impaired psychomotor function, and an increased risk of falls or cognitive impairment, particularly in elderly or debilitated patients. Concurrent use may also lower the seizure threshold, especially in patients with predisposing factors."
"Dextromethorphan, a serotonergic agent metabolized by CYP2D6, when combined with cariprazine, a dopamine D3/D2 receptor partial agonist, may increase the risk of serotonin syndrome due to additive serotonergic effects. Cariprazine can inhibit CYP2D6, reducing dextromethorphan clearance and elevating its plasma concentration, leading to enhanced serotonin activity. Clinically, patients may present with altered mental status, autonomic instability, and neuromuscular abnormalities."
"Dextromethorphan inhibits CYP2B6 and CYP2C9, which are involved in valproic acid metabolism. This results in decreased valproic acid clearance, potentially elevating valproic acid serum concentrations and increasing the risk of dose-dependent adverse effects such as hepatotoxicity, thrombocytopenia, and sedation. Concurrent use requires dose adjustment and close monitoring for signs of valproate toxicity."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BENZONATATE vs DEXTROMETHORPHAN POLISTIREX, answered by our medical review team.
BENZONATATE is a Antitussive that works by Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.. DEXTROMETHORPHAN POLISTIREX is a Antitussive that works by Dextromethorphan polistirex is an NMDA receptor antagonist and sigma-1 receptor agonist. It inhibits serotonin reuptake and acts on the brain stem cough center to elevate the threshold for coughing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BENZONATATE and DEXTROMETHORPHAN POLISTIREX depend on the specific clinical indication. These are both Antitussive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BENZONATATE is: 100 mg to 200 mg orally three times daily as needed for cough.. The standard adult dose of DEXTROMETHORPHAN POLISTIREX is: 30-60 mg orally every 12 hours; not to exceed 120 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BENZONATATE and DEXTROMETHORPHAN POLISTIREX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BENZONATATE is classified as Category A/B. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies not available. Theoretical risk of fetal bradycardia and respiratory depression if used near te. DEXTROMETHORPHAN POLISTIREX is classified as Category C. No well-controlled studies in pregnant women. Animal studies have not shown evidence of fetal harm. Based on limited human data, risk of major congenital malformations is low. Avoi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.